Multiple reports say OpenAI researcher Miles Wang is leaving (or planning to leave) the company to launch an AI-focused drug discovery startup. According to the accounts, Wang is in discussions with investors about raising substantial funding, with the startup’s valuation discussed around $2 billion. The reporting frames the effort as using AI to accelerate aspects of life-sciences research, including identifying and developing potential drug candidates. TechCrunch describes the situation as talks tied to investor interest in applying AI to breakthroughs in life sciences, while Seeking Alpha likewise ties Wang’s departure plans to the creation of the new venture and the scale of funding being considered.
The sources do not provide detailed information about the company’s specific technology, business model, or timeline beyond the fundraising and launch plans. They also do not clarify whether any funding has already been secured. Overall, the coverage centers on investor interest and the reported ambition to build a major AI drug discovery company anchored by Wang’s role as an OpenAI researcher.